In his presidential oration, Prof Shivaram Prasad Singh spoke about his journey as President, of INASL. He has achieved innumerable coveted awards and honors, organized many national and international conferences, workshops, consensus meetings, ..Read More

Infections in cirrhosis can be caused due to immune dysfunctions, altered microbiota and external factors including medications and exposures. In most cases, it has been seen that usual signs of infection may be absent in patients due to impaire..Read More

India witnesses a high prevalence of metabolic-associated steatotic liver disease (MASLD), and thus holds the opportunity to be the leader. Education and awareness about the disease are crucial both among physicians and the public. INASL Guidanc..Read More

NAFLD is the most common chronic liver disease across all age groups with a prevalence of 9.6% in lean and 38% to 45% in obese children, respectively. It is commonly seen in small-for-gestationalage and large-for-gestational-age infants, and chi..Read More

There is limited data on pediatric Budd-Chiari syndrome (BCS), hence diagnosis may be missed. A high index of suspicion and adequate work-up is needed. ‹ Adolescents and infants represent unique groups. Complete prothrombotic work-up should be ..Read More

Approximately 296 million people are chronically infected with hepatitis B and another 58 million people are living with hepatitis C, placing them at increased risk of developing cirrhosis, its complications including hepatocellular carcinoma (H..Read More

In autoimmune hepatitis (AIH), not all patients respond adequately to first-line treatment. When patients do not respond to or cannot tolerate the initial treatment, alternative management strategies are required, such as second-line therapies a..Read More

There is an unmet need to search for suitable noninvasive predictors of varices in patients with extrahepatic portal vein obstruction (EHPVO) like in cirrhosis. There is no definitive guideline on the use of noninvasive parameters for endoscopic..Read More

Pregnancy and cirrhosis require modification in the management protocol of AIH. Liver transplant remains the mainstay for AIHACLF. Recognize innate immune activation in patients with ACLF of any etiology. Therapeutic plasma exchange (PLEX) can b..Read More

Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are lifestyle diseases. As predicted there is going to be a phenomenal increase in the future. Lifestyle modifications (diet & exercise) are almost impossible to prac..Read More

Malnutrition, sarcopenia and frailty are not the same but interrelated.Sarcopenia assessment methods and definitions vary.It is very common in cirrhosis and affects wait-list mortality a well as post-transplant mortality in cirrhosis.F..Read More

Acute variceal bleeding (AVB) is a common and sometimes fatal complication seen in cirrhosis patients occurring at a rate of around 10% to 15% per year. Studies have shown the risk of re-bleeding at 5 days and 42 days range between 2% to 8% and ..Read More

The increasing prevalence of NAFLD/MAFLD (metabolic-associated fatty liver disease)/MASLD has led to an increasing number of ACLF cases in the affected population. Although there is adequate data available on ACLF in general, along with data on ..Read More

Etiology-specific management in ACLF can improve outcomes in selected cases.HBV-Flare causing ACLF can be treated with tenofovir/entecavir; alcohol-associated ACLF and autoimmune ACLF with steroids; Wilson disease ACLF with D-penicillamine.In al..Read More

Overt hepatic encephalopathy (HE) complicates the course of cirrhosis in one-third of the patients at some point during the clinical course leading to a high risk of mortality. Studies have shown that the rate of survival at 1 year and 5 years a..Read More

Hepatitis B reactivation is a potentially serious complication that can occur when patients with a history of HBV infection undergo immunosuppressive or immunomodulatory treatments. This issue has gained attention with the emergence of a new cla..Read More

Always test for coinfections in appropriate settings as coinfections lead to higher liver-related complications vs. mono-infections.All persons with HIV should be treated with potent antiretroviral therapy (irrespective of HIV RNA/CD4 counts), i..Read More

Administration of VEGF-C or D may ameliorate benign liver diseases by increasing lymphangiogenesis and lymphatic drainage. Blocking lymphangiogenesis could also be an appropriate option for diseases such as cholangiocarcinoma where tumor-induced..Read More